HeraMED Statistics
Total Valuation
HeraMED has a market cap or net worth of AUD 40.51 million. The enterprise value is 39.14 million.
| Market Cap | 40.51M |
| Enterprise Value | 39.14M |
Important Dates
The next estimated earnings date is Thursday, September 3, 2026.
| Earnings Date | Sep 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HeraMED has 1.16 billion shares outstanding. The number of shares has increased by 101.27% in one year.
| Current Share Class | 1.16B |
| Shares Outstanding | 1.16B |
| Shares Change (YoY) | +101.27% |
| Shares Change (QoQ) | +44.45% |
| Owned by Insiders (%) | 4.75% |
| Owned by Institutions (%) | 6.43% |
| Float | 814.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 122.60 |
| PB Ratio | 16.02 |
| P/TBV Ratio | 16.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 118.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.12.
| Current Ratio | 9.09 |
| Quick Ratio | 8.92 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -6,678.26 |
Financial Efficiency
Return on equity (ROE) is -223.73% and return on invested capital (ROIC) is -131.27%.
| Return on Equity (ROE) | -223.73% |
| Return on Assets (ROA) | -95.09% |
| Return on Invested Capital (ROIC) | -131.27% |
| Return on Capital Employed (ROCE) | -128.59% |
| Weighted Average Cost of Capital (WACC) | 4.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.06% in the last 52 weeks. The beta is 0.05, so HeraMED's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | +6.06% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 40.04 |
| Average Volume (20 Days) | 341,962 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HeraMED had revenue of AUD 330,441 and -3.47 million in losses. Loss per share was -0.00.
| Revenue | 330,441 |
| Gross Profit | -50,699 |
| Operating Income | -3.57M |
| Pretax Income | -3.47M |
| Net Income | -3.47M |
| EBITDA | -3.68M |
| EBIT | -3.57M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 2.93 million in cash and 291,255 in debt, with a net cash position of 2.64 million or 0.00 per share.
| Cash & Cash Equivalents | 2.93M |
| Total Debt | 291,255 |
| Net Cash | 2.64M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 2.53M |
| Book Value Per Share | 0.00 |
| Working Capital | 2.73M |
Cash Flow
| Operating Cash Flow | -3.66M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 22,297 |
| Net Borrowing | -68,917 |
| Free Cash Flow | -3.66M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | -15.34% |
| Operating Margin | -1,079.22% |
| Pretax Margin | -1,050.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeraMED does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -101.27% |
| Shareholder Yield | -101.27% |
| Earnings Yield | -8.57% |
| FCF Yield | -9.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |